CEO Alex Yang Buys $360K in Polaryx Therapeutics Stock at Significant Premium
PLYX sits 43% above its 52-week low of $2.07.
Summary
Polaryx Therapeutics CEO and 10% owner Alex Keun Mo Yang purchased $360,004 worth of common stock at a significant premium, signaling strong insider confidence following a recent private placement.
Key Events · Ownership and Investor Activity · PLYX
-
CEO and 10% Owner Purchase
Alex Keun Mo Yang, CEO and 10% owner, acquired $360,004 worth of common stock through Mstone Partners Healthcare Ltd.
-
Significant Premium Pricing
The shares were purchased at $4.07 per share, which is a substantial premium compared to the current market price of $2.95.
-
Follows Recent Private Placement
This purchase is part of the $10 million private placement announced on May 28, 2026, which addressed the company's short cash runway and going concern warning.
Analysis · PLYX · Life Sciences
This Form 4 filing reveals a critical vote of confidence from CEO Alex Keun Mo Yang, who, through Mstone Partners Healthcare Ltd, purchased $360,004 in Polaryx Therapeutics common stock. The purchase price of $4.07 per share is notably above the current market price of $2.95, indicating strong conviction in the company's future. This transaction is particularly important as it follows the company's recent disclosure of a going concern warning and a short cash runway, and it is part of the $10 million private placement announced today, which secured vital capital. The CEO's willingness to invest personally at a premium price underscores the perceived value and potential of the company's lead drug candidate, PLX-200, which recently received FDA Fast Track Designation.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLYX was trading at $2.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $144.4M. The 52-week trading range was $2.07 to $48.91. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.